Your search for rivaroxaban returned 143 results

Your search for rivaroxaban returned 143 results

Sort Results:

Relevant Recent
News

COMPASS Trial Ending Early After Reaching Superiority Endpoint

Janssen announced that the Phase 3 trial, COMPASS, is stopping earlier than planned based on the recommendation of the study's Independent Data Monitoring Committee (DMC), as the primary major adverse cardiovascular events (MACE) endpoint has reached its pre-specified criteria for superiority.
Drugs in the Pipeline

First Results of Rivaroxaban for VTE Treatment in Active Cancer

Janssen and Bayer presented the first results from their comprehensive research program, CALLISTO, which evaluated rivaroxaban for the treatment and prevention of venous thromboembolism (VTE) in patients with active cancer, at the 2015 American Society of Hematology (ASH) Annual Meeting.
News

AHA: Similar Stroke Risk on Stopping Rivaroxaban, Warfarin

For moderate-risk to high-risk patients with atrial fibrillation (AF), temporary or permanent discontinuation of anticoagulants is associated with a high risk of stroke, which is similar for rivaroxaban-treated or warfarin-treated patients
News

No Clear Benefit for Rivaroxaban After Hospital Discharge

The researchers found that a composite outcome of symptomatic venous thromboembolism or death due to venous thromboembolism occurred in 0.83% of patients in the rivaroxaban group and in 1.10% in the placebo group (hazard ratio, 0.76; 95% confidence interval, 0.52 to 1.09; P=0.14).